MaxHealthLabs Intra-Cellular Liposomal Vitamin D Supplement Outperforms in Clinical Study
Clinical study proves MaxHealthLabs Intra-Cellular Liposomal Vitamin D supplement significantly increases vitamin D plasma levels assuring customers they are the superior choice for vitamins and supplements.
In a controlled clinical test conducted by Xyrion Medical, MaxHealthLabs Intra-Cellular Liposomal Vitamin D supplement outperformed the other brand's oral vitamin D supplement considerably. MaxHealthLabs submitted the study to compare and measure each vitamin's effectiveness when reaching the bloodstream.
All the participant's blood levels were tested before and after the clinic trial. Although Brand X's vitamin did raise vitamin D blood levels for patients one and two by 33 to 9 percent respectively, MaxHealthLabs's vitamin raised vitamin D blood levels for patients one, two, and three by 111, 158, and 69 percent respectively. The study's conclusion demonstrates that MaxHealthLabs's D 25-hydroxy Vitamin significantly increases plasma levels of vitamin D.
These third party clinical blood studies show that MaxHealthLabs's products even go beyond expectations. "We are achieving levels at, near, and even sometimes above normal IV therapy levels of the same dosages. These are truly groundbreaking and pioneering results. And remember, we are talking about anti-oxidants, like Glutathione and Resveratrol, which have been clinically proven to be nearly impossible to achieve blood levels through a typical oral pill or tablet form," said MaxHealthLabs medical director, Dr. James Silverblatt, M.D.